SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
Tirzepatide glaucoma risk was lower than with selective glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
Open-angle glaucoma is linked to an increased risk for early-onset Alzheimer’s disease in middle-aged adults, especially men, ...
A risk score incorporating genetic variants for open-angle glaucoma is accurate enough to help with diagnosis of the condition, an interim study reveals. Although hundreds of genetic changes are ...
Glaucoma has a reputation as the "silent thief of sight," and for good reason. It is one of the leading causes of ...
A renewed focus on glaucoma comes with each new year, as January is Glaucoma Awareness Month.Glaucoma has been estimated to ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
DEAR DR. ROACH: I am a 77-year-old woman in good health. I walk daily. The only prescribed medications I am on are two different eye drops for glaucoma. My eye pressure is under control; I have it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback